Cargando…

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghimessy, Áron Kristof, Gellert, Áron, Schlegl, Erzsebet, Hegedus, Balazs, Raso, Erzsebet, Barbai, Tamas, Timar, Jozsef, Ostoros, Gyula, Megyesfalvi, Zsolt, Gieszer, Balazs, Moldvay, Judit, Renyi-Vamos, Ferenc, Lohinai, Zoltan, Hoda, Mir Alireza, Klikovits, Thomas, Klepetko, Walter, Laszlo, Viktoria, Dome, Balazs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827133/ https://www.ncbi.nlm.nih.gov/pubmed/31600989 http://dx.doi.org/10.3390/cancers11101514

Ejemplares similares

The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2016)

The landscape of small cell lung cancer metastases: Organ specificity and timing
por: Megyesfalvi, Zsolt, et al.
Publicado: (2021)

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
por: Gieszer, Balazs, et al.
Publicado: (2021)

Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor
por: Radeczky, Peter, et al.
Publicado: (2021)

Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression
por: Bánky, Balázs, et al.
Publicado: (2012)

Demonstration of a Melanoma-Specific CD44 Alternative Splicing Pattern That Remains Qualitatively Stable, but Shows Quantitative Changes during Tumour Progression
por: Raso-Barnett, Livia, et al.
Publicado: (2013)

Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2019)

Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer
por: Lohinai, Zoltan, et al.
Publicado: (2019)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer
por: Dora, David, et al.
Publicado: (2023)

Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy
por: Ladányi, Andrea, et al.
Publicado: (2022)

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
por: Klikovits, Thomas, et al.
Publicado: (2017)

Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients
por: Rojko, Livia, et al.
Publicado: (2020)

The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma
por: Barbai, Tamás, et al.
Publicado: (2015)

Apelin promotes lymphangiogenesis and lymph node metastasis
por: Berta, Judit, et al.
Publicado: (2014)

Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma
por: Rózsás, Anita, et al.
Publicado: (2013)

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
por: Dora, David, et al.
Publicado: (2020)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
por: Dora, David, et al.
Publicado: (2023)

Role of retinoic receptors in lung carcinogenesis
por: Bogos, Krisztina, et al.
Publicado: (2008)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

Molecular profiles of small cell lung cancer subtypes: therapeutic implications
por: Schwendenwein, Anna, et al.
Publicado: (2021)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021)

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015)

Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study
por: Megyesfalvi, Zsolt, et al.
Publicado: (2022)

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
por: Kovacs, Ildiko, et al.
Publicado: (2022)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
por: Markóczy, Zsolt, et al.
Publicado: (2018)

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
por: Torok, Szilvia, et al.
Publicado: (2017)

Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients
por: Marfil-Sánchez, Andrea, et al.
Publicado: (2021)

Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer
por: Dora, David, et al.
Publicado: (2021)

Intrathoracic solitary fibrous tumor – an international multicenter study on clinical outcome and novel circulating biomarkers
por: Ghanim, Bahil, et al.
Publicado: (2017)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS
por: Bonta, Maximilian, et al.
Publicado: (2016)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
por: Kenessey, István, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bcvcgdr31q6a9lpdoqrd01ei5b